-
Why This Teva Pharmaceutical Analyst Is Turning Bullish On The Austedo Franchise
Monday, February 12, 2024 - 12:53pm | 317Read More...Shares of Teva Pharmaceutical Industries Ltd (NYSE: TEVA) climbed in early trading on Monday, after several analysts raised their forecasts. The stock seems poised for a recovery due to the Austedo franchise, the improved positioning of the U.S. generics business and a better capital structure,...
-
Akorn Upgraded By Piper Jaffray On Improved Cost Structure, Product Potential
Wednesday, October 17, 2018 - 9:41am | 412Read More...A closer look at Akorn, Inc. (NASDAQ: AKRX)'s generics business led Piper Jaffray to turn bullish on the drug manufacturer's stock. The Analyst Analyst David Amsellem upgraded Akorn from Neutral to Overweight and raised the price target from $5 to $9. The Thesis Akorn's EBITDA has...
-
Piper Jaffray Loses Confidence In Insys Therapeutics, Downgrades Stock
Friday, March 9, 2018 - 2:27pm | 388Read More...Insys Therapeutics Inc (NASDAQ: INSY), a pharmaceutical company that focuses on a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients called Subsys, reported its fourth quarter results Thursday which prompted Piper Jaffray to downgrade the stock. The Analyst...
-
Piper Jaffray Upgrades Supernus Pharmaceutical On Possible Label Expansion For Seizure Drug
Thursday, June 1, 2017 - 3:14pm | 360Read More...Positive survey results have helped push Supernus Pharmaceutical Inc (NASDAQ: SUPN) up in Thursday trading and fueled an upgrade from Piper Jaffray. The survey conducted by Piper Jaffray suggests that "a better-tolerated, once-daily sodium channel blocker like Oxtellar XR would be well-...
-
Piper Jaffray Staying Bullish On Mallinckrodt
Wednesday, August 24, 2016 - 8:46am | 342Read More...Physicians and practices are likely become increasingly consistent with writing Acthar prescriptions, Piper Jaffray’s David Amsellem said in a report. While expressing optimism regarding Mallinckrodt PLC’s (NYSE: MNK) volume growth over the long-term, the analyst reiterated an...
-
Piper Jaffray On FDA Approval Of Insys Therapeutics' Anorexia Drug Syndros
Thursday, July 7, 2016 - 8:20am | 316Read More...Insys Therapeutics Inc (NASDAQ: INSY) announced the FDA approval of Syndros, and is waiting on a controlled substance designation from the Drug Enforcement Agency [DEA]. Piper Jaffray’s David Amsellem reiterated an Overweight rating on the company, with a price target of $28. Syndros is...
-
Jazz Pharma On Track To Report Top-Line, Late-Stage Results Of JZP-110 By December
Tuesday, May 17, 2016 - 4:11pm | 309Read More...Jazz Pharmaceuticals plc - Ordinary Shares (NASDAQ: JAZZ) "is well positioned to deliver a long-term EPS CAGR in at least the mid-to-high teens," according to a note from Piper Jaffray. Analyst David Amsellem noted that earnings growth will come from Xyrem, along with growing...
-
Piper Jaffray Analyst: Latest Report On Valeant 'Doesn't Surprise Me'
Thursday, May 12, 2016 - 3:38pm | 293Read More...David Amsellem of Piper Jaffray was asked for his opinion on reports that Valeant Pharmaceuticals Intl Inc (NYSE: VRX) has yet to proceed with proposed price cuts for some of its drugs. Speaking as a guest on CNBC, Amsellem said the report "doesn't surprise me" for several reasons...
-
Piper Jaffray Downgrades Allergan, Slashes Target To $238
Monday, April 18, 2016 - 10:45am | 314Read More...Piper Jaffray’s David Amsellem believes that although Allergan plc Ordinary Shares (NYSE: AGN) warrant a premium valuation to its specialty pharma peers, the current premium is “excessive.” The analyst downgraded the rating on the company from Overweight to Neutral, while...
-
Amsellem: Valeant Has No Floor
Tuesday, March 15, 2016 - 4:27pm | 324Read More...Valeant Pharmaceuticals Intl Inc (NYSE: VRX) finished Tuesday down 51 percent. The stock is down even further since Probes Reporter first reported the company was facing an undisclosed SEC probe on February 29. David Amsellem of Piper Jaffray recently told CNBC why he's Underweight Valeant...
-
Valeant's Calls To Analysts 'Raise Disclosure Questions'
Monday, March 7, 2016 - 3:37pm | 504Read More...Following an extended sick-leave, Valeant Pharmaceuticals Intl Inc (NYSE: VRX)'s CEO Mike Pearson has returned to his station at the company's helm. While a call to analysts was cancelled last week, Pearson personally made one-one-one calls to a few analysts, reaching out to those who,...
-
UPDATE: Piper Jaffray Upgrades Forest Laboratories, Previous Thesis is No Longer Tenable
Tuesday, November 26, 2013 - 11:57am | 186Read More...In a report published Tuesday, Piper Jaffray analyst David Amsellem upgraded the rating on Forest Laboratories (NYSE: FRX) from Underweight to Neutral, and raised the price target from $33.00 to $49.00. In the report, Piper Jaffray noted, “We are upgrading Forest to a Neutral from an Underweight...
-
UPDATE: Piper Jaffray Initiates Coverage on Discovery Laboratories on Emerging Respiratory Franchise at Breathtaking Value
Monday, November 11, 2013 - 10:15am | 185Read More...In a report published Monday, Piper Jaffray analyst David Amsellem initiated coverage on Discovery Laboratories (NASDAQ: DSCO) with an Overweight rating and $6.00 price target. In the report, Piper Jaffray noted, “We are initiating coverage of Discovery Labs with an Overweight rating and $6 price...
-
UPDATE: Piper Jaffray Downgrades Santarus Following Salix Acquisition Announcement
Friday, November 8, 2013 - 10:16am | 180Read More...In a report published Friday, Piper Jaffray analyst David Amsellem downgraded the rating on Santarus (NASDAQ: SNTS) from Overweight to Neutral, but raised the price target from $31.00 to $32.00. In the report, Piper Jaffray noted, “This afternoon, Santarus announced it has entered into a...
-
UPDATE: Piper Jaffray Upgrades Endo Health Solutions as Paladin Transaction is a Game-Changer
Wednesday, November 6, 2013 - 11:47am | 191Read More...In a report published Wednesday, Piper Jaffray analyst David Amsellem upgraded the rating on Endo Health Solutions (NASDAQ: ENDP) from Underweight to Neutral, and raised the price target from $26.00 to $58.00. In the report, Piper Jaffray noted, “With Endo announcing its plans to acquire Paladin...
